Prothena (PRTA) said Thursday the phase 2b study conducted by partner Roche evaluating prasinezumab for the treatment of early-stage Parkinson's disease missed its primary endpoint.
However, the study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints, the company said.
The results will therefore be used to inform future clinical development of the drug candidate as a potential disease-modifying treatment for patients with Parkinson's disease.
Meanwhile, Roche is further evaluating the data and will work with health authorities to determine the next steps.
Prothena's share price fell over 6% in recent premarket activity Thursday.
Price: 11.21, Change: -0.74, Percent Change: -6.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。